MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Pat DeMartino, MD; Douglas Carr, MD; Cat Livingston, MD; Caryn Mickelson, PharmD; Robin Moody, MPH; Eriko Onishi, MD; Bill Origer, MD; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Megan Herink, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Brandon Wells; Deborah Weston, JD; Kyle Hamilton; Trevor Douglass, DC, MPH; Jennifer Bowen; Melissa Yokoyama, PharmD

Audience: Rushi Parikh, Provention Bio*; Jason Kniffin, Novo Nordisk; Mark Kantor, AllCare Health; Sandee Merrick, Provention Bio; Bill Gittinger, MTPA; Brandie Feger, Advanced Health CCO; Chris Ferrin, Samaritan Health Plans; Gary Parenteau, Dexcom Inc; Lori McDermott, Viking HCS; Mark Wolber, Sunovion; Matt Worthy, OHSU; Melissa Abbott, Eisai; Stuart O’Brochta, Gilead; Nirmal Ghuman; Norman Navarro, Providence; Rushi Paikh, Provention Bio; Saghil Maleki, Takeda Pharmaceuticals; Shauna Wick; Stuart O’Brochta, Gilead; Sydney Wardan, UHA; Erin Nowak, AbbVie; Tiina Andrews, UHA; YJ Shukla, Moda Health EOCCO; Baltazar Diaz, Pacificsource; Melanie Greer, Legacy; Linda Finch, Biogen

(*) Provided verbal testimony

I. CALL TO ORDER

A. Roll Call & Introductions
   - Called to order at approx. 1:05 p.m., introductions by Committee and staff

B. Conflict of Interest Declaration – no new conflicts of interest were declared
C. Approval of Agenda and February 2023 Minutes presented by Roger Citron, RPh
   ACTION: Motion to approve, 2nd, all in favor with one abstention
D. Department Update provided by Andrew Gibler, PharmD
E. Legislative Update provided by Dee Weston, JD

II. CONSENT AGENDA TOPICS

A. Oncology Prior Authorization (PA) Updates
   Recommendation:
   - Add: Orserdu™ (elacestrant); Lunsumio™ (mosunetuzumab-axgb); Adstiladrin®
     (nadofaragene firadenovec-vncg) and Jaypirca™ (pirtobrutinib) to Table 1 in the
     Oncology Agents prior authorization (PA) criteria

B. Glaucoma Drugs Class Update & New Drug Evaluation (NDE)
   Recommendation:
   - No PDL changes recommended based on review of recently published evidence
   - Maintain omoidephag as non-preferred on the PDL
   - Evaluate costs in executive session
   ACTION: Motion to approve, 2nd, all in favor

III. DUR NEW BUSINESS

A. Generalized Anxiety Disorder (GAD) Update and Pregabalin Drug Use Evaluation:
   Andrew Gibler, PharmD and Sarah Servid, PharmD
   Recommendations:
   - Make pregabalin IR capsules preferred
   - Update Pregabalin PA criteria to: include GAD; remove gabapentin step therapy for all
     conditions; and suggest trial of a preferred gabapentinoid product
   - Align coverage criteria by removing PA for preferred pregabalin
   ACTION: The Committee recommended deferring the topic and asked staff to bring back
   evidence for safety and efficacy of pregabalin in GAD, and both gabapentin and
   pregabalin for other diagnoses for Committee to consider before opening coverage
   Motion to defer, 2nd, 8 in-favor with one opposed

B. Non-preferred Drugs in Select PDL Classes PA Update: Dave Engen, PharmD
   Recommendations:
   - Update Non-Preferred Drugs PA criteria to allow approval durations of up to 12
     months for patients with a previously approved PA
   ACTION: Motion to approve, 2nd, all in favor
C. **GLP-1 Receptor Agonists for Diabetes Policy Evaluation**: Melissa Yokoyama, PharmD

**Recommendations:**
- Maintain current PA policy

**ACTION:** Motion to approve, 2\(^{nd}\), all in favor

---

### IV. PREFERRED DRUG LIST (PDL) NEW BUSINESS

**A. Tzield™ (teplizumab-mzwv) NDE:** Kathy Sentena, PharmD

**Recommendations:**
- Include with Miscellaneous Antidiabetic Agents class on the PDL and designate as non-preferred
- Implement proposed PA criteria to limit use to people with stage 2 T1DM and high risk of progression to stage 3 T1DM

**ACTION:** The Committee amended the proposed criteria to add question #4 to deny coverage to those patients who have already progressed to stage 3 T1DM diagnosis; amend question #7 (previously #6) to include dysglycemia as defined by FPG, OGTT, 2-h plasma glucose or HbA1c; and remove the requirement that improvement be documented within one month of the renewal request

**Motion to approve, 2\(^{nd}\), all in favor**

**B. Growth Hormone Focused Class Update for Adults:** Dave Engen, PharmD

**Recommendations:**
- No PDL changes recommended based on review of recently published evidence
- Update PA criteria as proposed
- Evaluate costs in executive session

**ACTION:** Motion to approve, 2\(^{nd}\), all in favor

**C. Circadian Rhythm Sleep-Wake Disorders Indication Review:** Sarah Servid, PharmD

**Recommendations:**
- Continue to require PA to limit use to FDA-labeled and funded indications and update criterion as proposed
- If medically necessary for funded circadian rhythm sleep-wake disorders or if covered under EPSDT, require trial of a melatonin agonist or melatonin before approving sedating drugs and make at least one melatonin agonist preferred
- Evaluate costs in executive session

**ACTION:** Motion to approve, 2\(^{nd}\), all in favor
D. **Amyotrophic Lateral Sclerosis Class Update & NDE**: Sara Fletcher, PharmD  
**Recommendations:**  
- Designate riluzole as preferred and edaravone and sodium phenylbutyrate-taurursodiol as non-preferred on the PDL  
- Implement PA criteria for sodium phenylbutyrate-taurursodiol and update edaravone PA criteria as proposed  
- Evaluate costs in executive session  
**ACTION: Motion to approve, 2nd, all in favor**

V. **EXECUTIVE SESSION**

**Members Present:** Pat DeMartino, MD; Douglas Carr, MD; Cat Livingston, MD; Caryn Mickelson, PharmD; Eriko Onishi, MD; Bill Origer, MD; Eddie Saito, PharmD  

**Staff Present:** Sara Fletcher, PharmD; Sarah Servid, PharmD; David Engen, PharmD; Deanna Moretz, PharmD; Roger Citron, RPh; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Brandon Wells; Andrew Gibler, PharmD; Kyle Hamilton

VI. **RECONVENE for PUBLIC RECOMMENDATIONS**

A. **Glaucoma Drugs Class Update & NDE**  
**Recommendation:** Make brimonidine tartrate 0.1% ophthalmic drops preferred on the PDL  
**ACTION: Motion to approve, 2nd, all in favor**

B. **Growth Hormone Focused Class Update for Adults**  
**Recommendations:** Make no changes to the PDL  
**ACTION: Motion to approve, 2nd, all in favor**

C. **Circadian Rhythm Sleep-Wake Disorders Indication Review**  
**Recommendations:** Make ramelteon tablets preferred with PA  
**ACTION: Motion to approve, 2nd, all in favor**

D. **Amyotrophic Lateral Sclerosis Class Update &NDE**  
**Recommendations:** Make riluzole tablets preferred and riluzole film and suspension non-preferred  
**ACTION: Motion to approve, 2nd, all in favor**

VII. **ADJOURN**